6-Isopropyl-6-nor-lysergic acid diethylamide

Edit links
Source: Wikipedia, the free encyclopedia.
(Redirected from
IP-LAD
)
6-Isopropyl-6-nor-lysergic acid diethylamide
Clinical data
Routes of
administration		Oral
Legal status
Legal status
  • DE: NpSG (Industrial and scientific use only)
  • UK: Class A
Identifiers
  • (6aR,9R)-N,N-Diethyl-7-propan-2-yl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
JSmol)
  • CCN(CC)C(=O)[C@H]1CN([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)C(C)C
  • InChI=1S/C22H29N3O/c1-5-24(6-2)22(26)16-10-18-17-8-7-9-19-21(17)15(12-23-19)11-20(18)25(13-16)14(3)4/h7-10,12,14,16,20,23H,5-6,11,13H2,1-4H3/t16-,20-/m1/s1
  • Key:GLNOSFGSNDKLOC-OXQOHEQNSA-N
  (verify)

6-Isopropyl-6-nor-lysergic acid diethylamide (IP-LAD) is an

lysergic acid diethylamide (LSD) developed by the team of David E. Nichols. In studies on mice, it was found to be approximately 40% the potency of LSD, compared to the 60% increase in potency seen with ETH-LAD, 2-fold potency increase of AL-LAD, and roughly equivalent potency of PRO-LAD.[1]

References

  1. PMID 4032428
    .
Retrieved from "https://en.wikipedia.org/w/index.php?title=6-Isopropyl-6-nor-lysergic_acid_diethylamide&oldid=1162373656"
This page is based on the copyrighted Wikipedia article: IP-LAD. Articles is available under the CC BY-SA 3.0 license; additional terms may apply.Privacy Policy